NVAX

NanoFlu vaccine

Influenza

BLA: Preparing Submission

Exp Date

TBA

Amp Volatility Score

61%

Catalyst Info & Data Links

Catalyst Events


Clinical Trial

  • NCT04120194: Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

  • NCT03658629: Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

  • NCT03293498: Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

 

Prior Data Links


HC updated 5/21/20

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon